General description
INN
Daclatasvir + sofosbuvir
Medicine type
Chemical agent
EML status history
First added in 2021
(TRS
1035)
for
Chronic hepatitis C
Wikipedia
DrugBank
Recommendations
Section
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
- Oral > Solid: 60 mg + 400 mg
Indications